Parallax AHA Edition: 3 Trials that will change your practice with Dr Amit Khera | aha 21, hypertension clinical trials, pcsk9 inhibitors,

Parallax AHA Edition: 3 Trials that will change your practice with Dr Amit Khera

Average (ratings)

No ratings

•

Your rating

In this AHA 2021 episode of Parallax, Dr Ankur Kalra’s guest is Dr Amit Khera, Professor and Director of Preventive Cardiology at UT Southwestern Medical Center, Dallas and Vice Chair of the Scientific Sessions.

For this week’s show, Dr Khera selected three thought-provoking late-breaking trials that will inform or change clinical practice. Ankur and Amit discuss how the AVATAR trial will influence guidelines, and whether these findings could be translated to TAVR. Most importantly, they discuss how AVATAR’s results could inform patient decisions.
Next, Dr Khera highlights a randomized trial that was designed to address the needs of a larger population. The China Rural Hypertension Control Project offers exciting insights and an innovative framework for relying on social healthcare work.
Lastly, Dr Kalra and Dr Khera discuss a trial that investigated the LDL-cholesterol lowering efficacy of MK-0616. This oral PCSK9 Inhibitor may open the door for more patients in the future.

What were the key findings? What are the take-home messages? How will these 3 trials foster new opportunities for patients?

Trials covered in detail include:
• Aortic Valve Replacement versus Watchful Waiting in Asymptomatic Severe Aortic Stenosis: The Avatar Trial
• A Cluster Randomized Trial of a Village Doctor-Led Intervention on Blood Pressure Control: China Rural Hypertension Control Project
• The Clinical Safety, Pharmacokinetics, and LDL-Cholesterol Lowering Efficacy of MK-0616, an Oral PCSK9 Inhibitor

Questions and comments can be sent to “podcast@radcliffe-group.com” and may be answered by Ankur in the next episode. Guest @dramitkhera hosted by @AnkurKalraMD. Produced by @RadcliffeCARDIO.
Brought to you by Edwards: www.edwardstavr.com

Read MoreRead Less

Episodes

Up Next

EP 60: The Year 2021 in Review with Dr Sukh Nijjer – Part 1

EP60 • Dec 27, 2021 • 59m 18s

In the last Parallax episode of the year, Dr Ankur Kalra welcomed back Dr Sukh Nijjer, Interventional Cardiologist from Imperial College London, to review the most impactful events and advances in cardiology from 2021.

All Episodes

01: Conduction Abnormalities After TAVR/TAVI With Chad Kliger

EP01 • Apr 23, 2020 • 27m 44s

In our first episode, Ankur explains his vision for and inspiration to start ‘Parallax’, and speaks with Chad Kliger from Lenox Hill Hospital in New York about conduction abnormalities after transcatheter aortic valve replacement (TAVR/TAVI), a review article published in US Cardiology Review 13.1 Ankur and Chad look at conduction abnormalities after TAVR/TAVI with a focus on basic conduction system anatomy in relation to the aortic valve, the mechanism, incidence, predisposing factors for occurrence, impact on mortality and finally, proposed treatment algorithms for management. Hosted by @AnkurKalraMD. Produced by @RadcliffeCardiology.

... 4 5 6 7 8 9 10 11 12

Plant-Based Diet & Cardiovascular Health

06: Danielle Belardo @TheVeggieMD On A Whole-Food Plant-Based Diet And Cardiovascular Health

EP06 • Apr 23, 2020 • 34m 28s

In celebration of this month’s ‘National Eat Your Vegetables Day’, this week’s guest is @TheVeggieMD, one of the most prominent physicians on social media! Dr Danielle Belardo MD is a Cardiology Fellow, American Board of Internal Medicine certified and a member of the American College of Cardiology Nutrition and Lifestyle Sub-Committee.

In this episode, Ankur and Danielle speak about the evidence in favour of a whole-food plant-based diet to improve cardiovascular health, the ACC prevention guidelines, how to talk to patients about positive dietary change, the issue of lack of nutrition training in cardiovascular fellowships and what Danielle’s diet looks like as a busy whole-food plant-based cardiology fellow. On her own podcast ‘Nutrition Rounds’ Danielle has discussions about evidence-based plant-based nutrition with physicians who are leading experts in nutrition and health.

Hosted by @AnkurKalraMD. Produced by @RadcliffeCardiology.

Drug-Coated Balloons Small-Vessel CAD Brilakis - Megaly

05: Role Of Drug-Coated Balloons In Small-Vessel CAD With Emmanouil S Brilakis And Michael Megaly

EP05 • Apr 23, 2020 • 27m 43s

Listen to our first episode with two guests! Ankur spoke with Emmanouil S Brilakis, MD and Michael Megaly, MD from the Minneapolis Heart Institute, Abbott Northwestern Hospital about their article on the role of drug-coated balloons in small-vessel coronary artery disease (SVD) published in US Cardiology Review 13.1. Percutaneous coronary intervention of SVD remains challenging due to difficulties with device delivery and high restenosis rate, making drug-coated balloons an attractive emerging option in patients with SVD.

In this brilliant conversation, Ankur, Emmanouil and Michael unravel the potential advantages, challenges and practical realities of using drug-coated balloons in SVD, and the findings of the latest randomised controlled trials studying this area.

Hosted by @AnkurKalraMD. Produced by @RadcliffeCardiology. [Disclaimer: The use of drug-coated balloons in coronay intervention is still off-label; it has not been approved by the FDA.]

04: J Dawn Abbott On Recent Developments In Percutaneous Coronary Intervention

EP04 • Apr 23, 2020 • 34m 58s

We have observed a lot of developments in percutaneous coronary intervention (PCI) over the past 12 months with the publication of various studies and trials. This week, Ankur spoke with J. Dawn Abbott, MD, Associate Professor of Cardiology at Warren Medical School of Brown University about her recently published US Cardiology Review 13.1 article on the significant developments in PCI over the past 12 months.

Dawn is an associate editor of the journal Circulation: Cardiovascular Interventions and is widely known for her research program on PCI and peripheral arterial disease (PAD). Ankur and J. Dawn discuss multiple trials/studies that were published in 2018, including ORBITA, PIONEER-II and ABSORB. J. Dawn also shares her thoughts on the latest stent technologies.

Hosted by @AnkurKalraMD. Produced by @RadcliffeCardiology.

03: Athena Poppas on Effective Management of Hypertension

EP03 • Apr 23, 2020 • 29m 43s

This week’s podcast guest needs no introduction! Prof Athena Poppas is one of the most widely known cardiologists in the US and current Vice-President of the American College of Cardiology! Ankur spoke to Athena about her recently published US Cardiology Review 13.1 article on whether early management of hypertension by GPs can improve outcomes.

They discuss the importance of preventative medicine, their experience of reducing hypertension with non-pharmaceutical and pharmaceutical methods, and the significance of the integrated “team approach” when treating comorbid conditions such as hypertension. Athena also shares her thoughts on cardiologists’ responsibility to shape their patients’ lifestyle choices.

Hosted by @AnkurKalraMD. Produced by @RadcliffeCardiology.

02: Role Of High-Sensitivity Cardiac Troponin In ACS

EP02 • Apr 23, 2020 • 29m 55s

Ankur is back with his second #AudioArticle! This week he spoke with Santiago Garcia from the Minneapolis Heart Institute about Santiago’s US Cardiology Review 13.1 article on the role of high-sensitivity cardiac troponin (hscTn) assays and their ability to rapidly rule in or rule out acute coronary syndrome (ACS) with improved sensitivity.

Chest pain is one of the most common reasons for an emergency room visit in the US, with almost 6 million ER visits annually, yet there is no consensus on how to compare the results from various hscTn assays. Tune in to hear Santiago outline the advantages and limitations of using hscTn as a standard biomarket to evaluate patients with suspected ACS in the ER.

Hosted by @AnkurKalraMD. Produced by @RadcliffeCardiology.

... 18 19 20 21 22 23